Systemic nonbiologic therapies, targeted therapies, or biologics are commonly used to manage moderate to severe psoriasis, with higher efficacy for biologic than nonbiologic agents.
1,2 With the fast emergence of these new therapeutic agents, evaluating long-term comparative safety in a real-world setting is needed because patients with moderate to severe psoriasis may be at increased risk of serious infection, depending on the biologic agent used.
3